Free Trial
→ I’m sounding the alarm (From Porter & Company) (Ad)tc pixel Free AVGR Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Avinger (AVGR) Competitors

Avinger logo
Compare

AVGR vs. NDRA, CODX, CLGN, NXGL, and INBS

Should you be buying Avinger stock or one of its competitors? The main competitors of Avinger include ENDRA Life Sciences (NDRA), Co-Diagnostics (CODX), CollPlant Biotechnologies (CLGN), NexGel (NXGL), and Intelligent Bio Solutions (INBS). These companies are all part of the "medical equipment" industry.

How does Avinger compare to ENDRA Life Sciences?

Avinger (NASDAQ:AVGR) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

ENDRA Life Sciences has lower revenue, but higher earnings than Avinger. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avinger$7.65M0.21-$18.32M-$11.06N/A
ENDRA Life SciencesN/AN/A-$7.03M-$8.92N/A

Avinger's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
AvingerN/A N/A N/A
ENDRA Life Sciences N/A -397.71%-190.73%

In the previous week, Avinger's average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company Overall Sentiment
Avinger Neutral
ENDRA Life Sciences Neutral

Avinger has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500.

ENDRA Life Sciences has a consensus target price of $30.00, indicating a potential upside of 512.87%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Avinger.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avinger
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

18.3% of Avinger shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 42.8% of Avinger shares are held by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Avinger beats ENDRA Life Sciences on 7 of the 12 factors compared between the two stocks.

How does Avinger compare to Co-Diagnostics?

Co-Diagnostics (NASDAQ:CODX) and Avinger (NASDAQ:AVGR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Co-Diagnostics currently has a consensus target price of $67.50, indicating a potential upside of 4,145.28%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than Avinger.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Co-Diagnostics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Avinger
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Co-Diagnostics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Avinger has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

Avinger has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Co-Diagnostics$620K9.23-$46.90M-$29.73N/A
Avinger$7.65M0.21-$18.32M-$11.06N/A

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 18.3% of Avinger shares are owned by institutional investors. 5.4% of Co-Diagnostics shares are owned by insiders. Comparatively, 42.8% of Avinger shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Co-Diagnostics had 1 more articles in the media than Avinger. MarketBeat recorded 1 mentions for Co-Diagnostics and 0 mentions for Avinger. Co-Diagnostics' average media sentiment score of 0.00 equaled Avinger'saverage media sentiment score.

Company Overall Sentiment
Co-Diagnostics Neutral
Avinger Neutral

Avinger has a net margin of 0.00% compared to Co-Diagnostics' net margin of -7,546.43%. Avinger's return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Co-Diagnostics-7,546.43% -125.46% -109.64%
Avinger N/A N/A N/A

Summary

Avinger beats Co-Diagnostics on 10 of the 15 factors compared between the two stocks.

How does Avinger compare to CollPlant Biotechnologies?

Avinger (NASDAQ:AVGR) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Avinger has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

CollPlant Biotechnologies has lower revenue, but higher earnings than Avinger. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avinger$7.65M0.21-$18.32M-$11.06N/A
CollPlant Biotechnologies$2.37M2.43-$11.49M-$1.35N/A

CollPlant Biotechnologies has a consensus target price of $11.50, suggesting a potential upside of 2,774.28%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Avinger.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avinger
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CollPlant Biotechnologies
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Avinger's average media sentiment score of 0.00 equaled CollPlant Biotechnologies'average media sentiment score.

Company Overall Sentiment
Avinger Neutral
CollPlant Biotechnologies Neutral

Avinger has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -353.70%. Avinger's return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
AvingerN/A N/A N/A
CollPlant Biotechnologies -353.70%-161.69%-109.44%

18.3% of Avinger shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 42.8% of Avinger shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

CollPlant Biotechnologies beats Avinger on 8 of the 14 factors compared between the two stocks.

How does Avinger compare to NexGel?

Avinger (NASDAQ:AVGR) and NexGel (NASDAQ:NXGL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Avinger has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, NexGel has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

18.3% of Avinger shares are held by institutional investors. Comparatively, 2.2% of NexGel shares are held by institutional investors. 42.8% of Avinger shares are held by company insiders. Comparatively, 20.6% of NexGel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

NexGel has higher revenue and earnings than Avinger. NexGel is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avinger$7.65M0.21-$18.32M-$11.06N/A
NexGel$11.42M0.46-$3M-$0.38N/A

In the previous week, Avinger's average media sentiment score of 0.00 equaled NexGel'saverage media sentiment score.

Company Overall Sentiment
Avinger Neutral
NexGel Neutral

NexGel has a consensus target price of $2.00, suggesting a potential upside of 238.64%. Given NexGel's stronger consensus rating and higher possible upside, analysts plainly believe NexGel is more favorable than Avinger.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avinger
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NexGel
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Avinger has a net margin of 0.00% compared to NexGel's net margin of -26.27%. Avinger's return on equity of 0.00% beat NexGel's return on equity.

Company Net Margins Return on Equity Return on Assets
AvingerN/A N/A N/A
NexGel -26.27%-56.90%-28.42%

Summary

Avinger and NexGel tied by winning 7 of the 14 factors compared between the two stocks.

How does Avinger compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and Avinger (NASDAQ:AVGR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

In the previous week, Intelligent Bio Solutions had 1 more articles in the media than Avinger. MarketBeat recorded 1 mentions for Intelligent Bio Solutions and 0 mentions for Avinger. Intelligent Bio Solutions' average media sentiment score of 0.20 beat Avinger's score of 0.00 indicating that Intelligent Bio Solutions is being referred to more favorably in the media.

Company Overall Sentiment
Intelligent Bio Solutions Neutral
Avinger Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intelligent Bio Solutions
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Avinger
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Avinger has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -315.33%. Avinger's return on equity of 0.00% beat Intelligent Bio Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Bio Solutions-315.33% -200.68% -97.31%
Avinger N/A N/A N/A

33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 18.3% of Avinger shares are owned by institutional investors. 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Comparatively, 42.8% of Avinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Intelligent Bio Solutions has higher earnings, but lower revenue than Avinger. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Bio Solutions$3.05M1.59-$10.57M-$14.82N/A
Avinger$7.65M0.21-$18.32M-$11.06N/A

Intelligent Bio Solutions has a beta of 4.24, indicating that its stock price is 324% more volatile than the S&P 500. Comparatively, Avinger has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.

Summary

Intelligent Bio Solutions and Avinger tied by winning 7 of the 14 factors compared between the two stocks.

Get Avinger News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVGR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVGR vs. The Competition

Export
MetricAvingerMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$1.57M$7.06B$6.25B$11.76B
Dividend YieldN/A1.74%2.74%5.26%
P/E Ratio-0.0429.5629.2427.07
Price / Sales0.2155.84504.6873.40
Price / CashN/A24.3243.3053.90
Price / Book-0.107.299.676.69
Net Income-$18.32M$158.34M$3.55B$332.64M

Avinger Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVGR
Avinger
N/A$0.47
flat		N/AN/A$1.57M$7.65MN/A70
NDRA
ENDRA Life Sciences
2.1412 of 5 stars		$4.85
+5.7%		$30.00
+518.6%		-22.8%$6.02MN/AN/A20
CODX
Co-Diagnostics
1.0541 of 5 stars		$1.53
-6.1%		$67.50
+4,311.8%		-84.9%$5.51M$622.49KN/A100
CLGN
CollPlant Biotechnologies
1.4472 of 5 stars		$0.37
-4.5%		$11.50
+2,987.2%		-80.9%$5.37M$2.37MN/A70
NXGL
NexGel
1.9515 of 5 stars		$0.60
-1.0%		$2.00
+233.3%		-77.4%$5.09M$11.42MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AVGR) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Did you miss The Dark AI Summit?
Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...
Brownstone Research | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel